AZN•benzinga•
AstraZeneca Unveils Early Data From Chinese-Firm Partnered Oral Weight Loss Drug
Summary
AstraZeneca and Eccogene revealed promising trial data on ECC5004, an oral GLP-1 receptor agonist for obesity, showing safety, tolerability, and convenient dosing.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on November 4, 2024 by benzinga